X
Pfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drug
https://pharmaphorum.com/news/pfizer-inks-deal-with-ionis-and-akcea-for-potential-blockbuster-diabetes-and-nash-drug/
Ionis
Alnylam’s Onpattro is first ever FDA-approved RNAi drug
Onpattro will cost $450,000 a year
Ionis hit by safety concerns, rivals Alnylam benefit
Biotech insists drug for rare inherited disorder is still approvable.
Biogen courts controversy with $750k-a-year rare disease drug
Biogen’s SMA treatment approved – but price is $125,000 per dose
1 2